NCT03430037
Alleviation by Fisetin of Frailty, Inflammation, and Related Measures in Older Women
Enrolling by Invitation
PHASE2Ages 70+InterventionalTreatmentMayo ClinicInvestigator-initiated
~40 participants
Updated 2026-05-11 on ClinicalTrials.gov
What's tested:FisetinPlacebo oral capsule
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Improved 6 minute walk
Measured over One Month
Conditions
Where it's being run
1 sites across 1 statesMinnesota1
Study leadership
- Robert J Pignolo, MD, PhD · PRINCIPAL_INVESTIGATOR · Mayo Clinic
- Sundeep Khosla, MD · PRINCIPAL_INVESTIGATOR · Mayo Clinic
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Healthy postmenopausal women
Age ≥ 70 years
Exclusion
Abnormality in any of the screening laboratory studies (see below)
Presence of significant liver or renal disease
Malignancy (including myeloma)
Malabsorption
Hypoparathyroidism
Hyperparathyroidism
Acromegaly
Cushing's syndrome
Hypopituitarism
Gastric bypass/reduction
Malabsorption issues
Crohn's
Myopathies (increased or low calcium, vitamin D deficiency, elevated creatine kinase or ESR)
If diabetic AND on sulfonylureas (like glipizide, glimepiride, glyburide), SGLT2 inhibitors (like dapagliflozin and empagliflozin), or insulin
Undergoing treatment with any medications that affect bone turnover, including the following:
adrenocorticosteroids (\> 3 months at any time or \> 10 days within the previous yr), anticonvulsant therapy (within the previous year),
pharmacological doses of thyroid hormone (causing decline of thyroid stimulating hormone below normal),
calcium supplementation of \> 1200 mg/d (within the preceding 3 months),
bisphosphonates (within the past 3 yrs),
denosumab,
estrogen (E) therapy or treatment with a selective E receptor modulator, or teriparatide (within the past yr).
Subjects with a fracture within the past year
Subjects taking potentially senolytic agents within the last year: Fisetin, Quercetin, Luteolin, Dasatinib, Piperlongumine, or Navitoclax
Subjects currently taking drugs that induce cellular senescence: alkylating agents, anthracyclines, platins, other chemotherapy
QTc \>450 msec
Inability to provide informed consent
Total bilirubin \>2X upper limit
Inability to tolerate oral medication
eGFR \< 15 ml/ min/ 1.73 m2
Subjects on therapeutic doses of anticoagulants (e.g., warfarin, heparin, low molecular weight heparin, factor Xa inhibitors, etc.)
Subjects taking the following antimicrobial agents: Aminoglycosides, Azole antifungals (fluconazole, miconazole, voriconazole, itraconazole), Macrolides (clarithromycin, erythromycin), Antivirals (nelfinavir, indinavir, saquinavir, ritonavir, elbasvir/grazoprevir), Rifampin
Subjects taking proton pump inhibitors who are unable or unwilling to reduce or hold therapy prior to and during the 2-day Fisetin dosing
Subjects taking the following other drugs if they cannot be held for at least 2 days before and during administration of Fisetin: digoxin, lithium, all statins, repaglidine, bosentan, gemfibrozil, olmesartan, enalapril, valsartan, methotrexate, corticosteroids, thyroid hormones, eluxadoline, eltrombopag, nitroglycerin, pioglitazone, glyburide, enzalutamide, ezetimibe, colchicine, imatinib, cyclosporine, tacolimus, sirolimus, carbamazepine, flecainide, phenytoin, phenobarbital, rifampicin, theophylline, warfarin, heparin, full dose ASA, clopidogrel, celecoxib, desipramine, thioridazine, venlafaxine, tizanidine, atomoxetine, voriconazole, citalopram, diazepam, escitalopram, propranolol, clozapine, cyclobenzaprine, mexiletine, olanzapine, ondansetron, riluzole
In order to ensure vitamin D sufficiency, we will also exclude subjects with serum 25-hydroxyvitamin D levels of \< 20 ng/ml.
What this trial measures
- Improved 6 minute walkOne Month
Improved gait speed